The ELIXA biomarker study evaluated protein biomarkers as clinical risk factors to identify people with type 2 diabetes and acute coronary syndrome who are at highest risk for cardiovascular (CV) outcomes and death. Professor Hertzel Gerstein (McMaster University, Hamilton, ON, Canada) discusses the outcomes of the ELIXA biomarker study and the implications of the findings for clinical practice.
The abstract entitled ‘Cardiovascular Outcomes in People with Type 2 Diabetes and Acute Coronary Syndrome—The ELIXA Biomarker Study‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
Questions:
- Please can you describe the rationale for investigating novel protein biomarkers as risk factors for cardiovascular outcomes? (0:27)
- How did the ELIXA biomarker study evaluate potential novel protein risk factors and what were its key findings? (1:42)
- In your opinion, what are the implications of these results for clinical practice? (3:12)
Disclosures: Hertzel Gerstein is on the advisory board and a consultant for Sanofi. Hertzel Gerstein has received grant/research support and honorarium from Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
